Renalytix plc last reported quarterly results on Oct 1, 2024, for Q1 FY2025 (the quarter ended Sep 30, 2024): revenue of $522,000 (+13.7% year over year) and diluted EPS of -$0.04. It usually reports 1–46 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–46 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 1, 2024
1 days after quarter end
|
Q1 FY2025
ended Sep 30, 2024
|
1
+13.7%
|
-5
+53.4%
|
-0.04
+63.6%
|
|
May 15, 2024
45 days after quarter end
|
Q3 FY2024
ended Mar 31, 2024
|
1
|
-8
|
-0.08
|
|
Feb 15, 2024
46 days after quarter end
|
Q2 FY2024
ended Dec 31, 2023
|
1
|
-8
|
-0.09
|
|
Nov 14, 2023
45 days after quarter end
|
Q1 FY2024
ended Sep 30, 2023
|
0
|
-10
|
-0.11
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.